<DOC>
	<DOCNO>NCT00359671</DOCNO>
	<brief_summary>A study evaluate safety tolerability MK6592 combination anti-cancer drug adult patient advance solid tumor .</brief_summary>
	<brief_title>Treatment With MK6592 Anti-cancer Drug Patients With Advanced Solid Tumors ( 6592-001 )</brief_title>
	<detailed_description />
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Patients advance solid tumor ( metastatic local ) unresponsive standard therapy , progressed standard therapy , standard therapy exists . No limit number prior treatment regimen Patients may fully active without physical restriction , ambulatory restriction strenuous physical activity , ambulatory capable selfcare work activity ( i.e. , Eastern Cooperative Oncology Group performance status great equal 2 ) Demonstrates adequate organ function ( liver , kidney , hematologic ) Chemotherapy radiation therapy within 2 week dose ; unresolved side effect ( ) prior treatment regimen Participation investigational study within 14 day dose Primary central nervous system tumor Active brain spinal cord metastasis . Patients complete course therapy CNS metastasis may eligible consider clinically stable 3 month prior study entry Symptoms fluid abdomen around lung Requires certain drug product know metabolized liver enzyme CYP3A4</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>